David Granlund

Research
My research interests are in industrial organization and health, behavioral, political, and public economics. Most of the research I have performed in the first three fields concerns the pharmaceutical market.

CV

Articles in international scientific journals

Direct and indirect savings from parallel imports in Sweden, Health Economics Review 12, article number 46, 2022. https://doi.org/10.1186/s13561-022-00391-x.

Quantifying the Zero-Price Effect in the Field: Evidence from Swedish Prescription Drug Choices, with A Ching and D Sundström, Journal of the Association for Consumer Research 7(2), 175–185. 2002 https://doi.org/10.1086/718460.

The price effects of competition from parallel imports and therapeutic alternatives: Using dynamic models to estimate the causal effect on the extensive and intensive margins, Review of Industrial Organization 60(1), 63–92,  https://doi.org/10.1007/s11151-021-09834-x.

A new approach to estimating state dependence in consumers' brand choices applied to 762 pharmaceutical markets, Journal of Industrial Economics 69(2), 443–483, 2021. WP-version

Can private provision of primary care contribute to the spread of antibiotic resistance? A study of antibiotic prescription in Sweden, with Y V Zykova, PharmacoEconomics – Open 5(2), 187–195, 2020.

Price competition in pharmaceuticals – evidence from 1303 Swedish markets, with M A Bergman, Journal of Health Economics 61, 1-12, 2018.         Results from three extensions  Post-refereeing-version

Physicians prescribing originals causes welfare losses, with D Sundström, Economics Letters 170, 143-146, 2018. Post-refereeing-version

Squeezing the last drop out of your suppliers: an empirical study of market-based purchasing policies for generic pharmaceuticals, with M Bergman and N Rudholm, Oxford Bulletin of Economics and Statistics 79(6), 969-996, 2017.

Federal Subsidization of State Expenditure to Reduce Political Budget Cycles, with T Aronsson, International Tax and Public Finance 24(3), 536-545, 2017.
Free view-only version
Post-refereeing-version

Reforming the Swedish pharmaceuticals market: Consequences for costs per defined daily dose, with M Bergman and N Rudholm. International Journal of Health Economics and Management, 16(3), 201-214, 2016.
Free view-only version
Post-refereeing-version

EU Enlargement, Parallel Trade and Price Competition in Pharmaceuticals: Has the Price Competition increased? With M Y Köksal-Ayhan. The B.E. Journal of Economic Analysis and Policy 16(2), 1069–1092, 2016.

Public provision and cross-border health care, with M Wikström, Forum for Health Economics & Policy 19(2), 157-177, 2016 (Open Access).

Gender Norms, Work Hours, and Corrective Taxation, with T Aronsson, Journal of Behavioral and Experimental Economics 56, 33-39, 2015. (Open Access)

The effect of pharmacies' right to negotiate discounts on the market share of parallel imported pharmaceuticals. The B.E. Journal of Economic Analysis and Policy 15, 1197-1235, 2015.

Parallel Imports and Mandatory Substitution Reform – A Kick or A Muff for Price Competition? The European Journal of Health Economics, 16(9), 969-983, 2015 (with M Koksal-Ayhan)
Free view-only version
Post-refereeing-version

Introducing waiting times for health care in a labor supply model for sickness absence, with D Andrén, Nordic Journal of Health Economics 3, 34-46, 2014 (Open Access)
WP-version

Present-Biased Preferences and Publicly Provided Private Goods. FinanzArchiv/Public Finance Analysis 70(2), 169-199, 2014. (with T Aronsson)
Post-refereeing-version
WP-version

The prescribing physician's influence on consumer choice between medically equivalent pharmaceuticals. Review of Industrial Organization 41, 207-222, 2012. (with N Rudholm)
Free view-only version
Post-refereeing-version

Electoral accountability in a country with two-tiered government, Public Choice 148, 531-546, 2011.
Free view-only version
Post-refereeing-version

Public goods and optimal paternalism under present-biased preferences, Economics Letters 113, 54-57, 2011 (with T Aronsson).
Post-refereeing-version

Price and welfare effects of a pharmaceutical substitution reform, Journal of Health Economics 29, 856-865, 2010.
Post-refereeing-version

Consumer information and pharmaceutical prices: Theory and Evidence, Oxford bulletin of Economics and Statistics 73(2), 230-254, 2011. (with N Rudholm)
Free view-only version
WP-version
Additional results

The effect of health care expenditure on sickness absence, The European Journal of Health Economics 11, 555-568, 2010.
Free view-only version
Post-refereeing-version

Inequality in mortality in Vietnam during a period of rapid transition, Social Science & Medicine 70, 232-239, 2010. (with N T Chuc, H D Phuc and L Lindholm)
Post-refereeing-version

Are private physicians more likely to veto generic substitution of prescribed pharmaceuticals? Social Science & Medicine 69, 1643-1650, 2009.
Post-refereeing-version
Additional results

Sickness absence and health care in an economic federation, International Tax and Public Finance 14, 503-524, 2007.
Free view-only version
Post-refereeing-version

Fixed budgets as a cost containment measure for pharmaceuticals, The European Journal of Health Economics 7, 37-45, 2006 (with N Rudholm and M Wikström)
Free view-only version
WP-version

Thesis:
Economic policy in health care – sickness absence and pharmaceutical costs

Current research projects: The effect of the number of bidders on the probability of collusion [Effekten av antal budgivare på sannolikheten för prissamordningar] Financed by the Swedish Competition Authority [Konkurrensverket]. 2020-2022. Project leader: Niklas Rudholm, Institute of retail economics.

Competition about garbage—an analysis of the waste incineration market [Konkurrens om sopor – En analys av marknaden för avfallsförbränning] Financed by the Swedish Competition Authority [Konkurrensverket]. September 2019–September2022.